



SAB BIO to Participate in Chardan 10th Annual Healthcare Conference

October 14, 2026 12:30 PM EDT

MIAMI, Oct. 14, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: [SABS](#)), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that members of its management team will participate in the upcoming Chardan 10th Annual Healthcare Conference:

Date: October 20, 2026

Time: 11:15 - 11:30 a.m. ET

Format: Fireside Chat

Presenter: Samuel J. Reich, Chief Executive Officer

Location: New York, NY

Webcast: Register [here](#)

SAB BIO management will be available for one-on-one meetings during the conference. Interested parties should contact their conference representative to arrange a meeting. To access replay webcasts of investor events, please visit the [Investors & Media](#) section of SAB BIO's website at www.sab.bio.

About SAB BIO

SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomal cattle, or Tc-Bovine, to produce hIgG. SAB BIO's drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases. The Company's lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. SAB-142 is currently being evaluated in newly diagnosed Stage 3 autoimmune T1D patients in a registrational Phase 2b clinical trial called SAFEGUARD. For more information, visit www.sab.bio.

CONTACTS

Investor Relations:

Christine Ryan

ir@sab.bio

Media:

Sheila Carlson

media@sab.bio